Keith S. Manchester
Known title: DirectorCIK: 0001244828
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
ABUS Featured in Whale Alert List of 10 Health Care Stocks. Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.
Transaction History
| ROIV | ▲ Buy | Grant | 5,054 | $0 | 9/16/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 12,380 | $437K | 6/30/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 200,000 | $7.1M | 6/30/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 200,000 | $6.9M | 6/29/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 600,000 | $20.8M | 6/29/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 300,783 | $10.2M | 6/26/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 325,000 | $11.1M | 6/26/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 150,784 | $4.0M | 2/13/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 225,000 | $6.0M | 2/13/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 150,000 | $4.0M | 2/12/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 275,000 | $7.4M | 2/12/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 425,000 | $11.3M | 2/11/2026 | View on chart |
| ROIV | ▼ Sell | Open Market | 432,718 | $10.0M | 12/17/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 155,076 | $3.6M | 12/17/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 189,538 | $4.4M | 12/17/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 275,000 | $6.3M | 12/16/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 642,282 | $14.8M | 12/16/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 125,000 | $2.5M | 11/19/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 175,000 | $3.5M | 11/19/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 150,000 | $3.0M | 11/19/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 850,000 | $17.2M | 11/19/2025 | View on chart |
| ROIV | ▲ Buy | Grant | 14,524 | $0 | 9/10/2025 | View on chart |
| ROIV | ▼ Sell | Other | 1,170,646 | $0 | 6/25/2025 | View on chart |
| ROIV | ▼ Sell | Other | 6,837,266 | $0 | 6/25/2025 | View on chart |
| ROIV | ▼ Sell | Other | 6,205,368 | $0 | 6/25/2025 | View on chart |
| ROIV | ▼ Sell | Other | 3,176,245 | $0 | 6/25/2025 | View on chart |
| ROIV | ▼ Sell | Open Market | 134,948 | $1.6M | 9/25/2024 | View on chart |
| ROIV | ▼ Sell | Open Market | 368,052 | $4.3M | 9/24/2024 | View on chart |
| ROIV | ▲ Buy | Grant | 16,406 | $0 | 9/10/2024 | View on chart |
| ABUS | ▲ Buy | Option Exercise | 54,915 | $31K | 8/14/2024 | View on chart |
| ABUS | ▼ Sell | Open Market | 8,846 | $33K | 8/14/2024 | View on chart |
| ROIV | ▼ Sell | Other | 11,325,233 | $0 | 3/7/2024 | View on chart |
| ROIV | ▼ Sell | Other | 2,260,661 | $0 | 3/7/2024 | View on chart |
| ROIV | ▼ Sell | Other | 5,594,064 | $0 | 3/7/2024 | View on chart |
| ROIV | ▼ Sell | Other | 11,077,765 | $0 | 3/7/2024 | View on chart |
| ROIV | ▼ Sell | Open Market | 2,285,783 | $26.4M | 9/28/2023 | View on chart |
| ROIV | ▼ Sell | Open Market | 3,059,368 | $35.3M | 9/28/2023 | View on chart |
| ROIV | ▼ Sell | Open Market | 1,104,599 | $12.8M | 9/28/2023 | View on chart |
| ROIV | ▼ Sell | Open Market | 446,394 | $5.2M | 9/28/2023 | View on chart |
| ROIV | ▲ Buy | Grant | 17,825 | $0 | 9/12/2023 | View on chart |
| ROIV | ▼ Sell | Open Market | 1,092,355 | $5.2M | 11/10/2022 | View on chart |
| ROIV | ▼ Sell | Open Market | 372,427 | $1.8M | 11/10/2022 | View on chart |
| ROIV | ▼ Sell | Open Market | 2,311,643 | $11.0M | 11/10/2022 | View on chart |
| ROIV | ▼ Sell | Open Market | 146,079 | $694K | 11/10/2022 | View on chart |
| ROIV | ▼ Sell | Other | 1,196,200 | — | 11/9/2022 | View on chart |
| ROIV | ▲ Buy | Grant | 52,142 | $0 | 9/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Roivant Sciences receives downgrades from Wolfe Research and analyst
Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.
Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.